Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nutriband Inc (NTRB)

Nutriband Inc (NTRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,709
  • Shares Outstanding, K 12,175
  • Annual Sales, $ 2,140 K
  • Annual Income, $ -10,480 K
  • EBIT $ -9 M
  • EBITDA $ -5 M
  • 60-Month Beta 1.89
  • Price/Sales 25.77
  • Price/Cash Flow N/A
  • Price/Book 7.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/26
See More
  • Average Estimate -1.89
  • Number of Estimates 1
  • High Estimate -1.89
  • Low Estimate -1.89
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -950.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.34 +9.22%
on 12/23/25
5.45 -13.08%
on 12/11/25
+0.06 (+1.28%)
since 11/24/25
3-Month
4.34 +9.22%
on 12/23/25
8.63 -45.05%
on 10/08/25
-2.53 (-34.80%)
since 09/24/25
52-Week
3.72 +27.34%
on 12/27/24
11.78 -59.76%
on 01/23/25
+0.85 (+21.82%)
since 12/24/24

Most Recent Stories

More News
Nutriband (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced...

NTRB : 4.74 (+4.64%)
BMWYY : 29.2000 (+4.58%)
Nutriband (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction should not be conflated with “FDA”-approved...

NTRB : 4.74 (+4.64%)
Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent...

NTRB : 4.74 (+4.64%)
NTRBW : 1.5100 (+1.34%)
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment...

NTRB : 4.74 (+4.64%)
NTRBW : 1.5100 (+1.34%)
Nutriband (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21

Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern...

NTRB : 4.74 (+4.64%)
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference

Orlando, Florida--(Newsfile Corp. - November 24, 2025) - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman and Co-Founder, Serguei Melnik will present at NobleCon21 - Noble...

NTRB : 4.74 (+4.64%)
Nutriband (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food...

NTRB : 4.74 (+4.64%)
BMWYY : 29.2000 (+4.58%)
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received...

NTRB : 4.74 (+4.64%)
NTRBW : 1.5100 (+1.34%)
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received...

NTRB : 4.74 (+4.64%)
NTRBW : 1.5100 (+1.34%)
Nutriband (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei...

NTRB : 4.74 (+4.64%)

Business Summary

Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company is engaged in developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. Nutriband...

See More

Key Turning Points

3rd Resistance Point 4.97
2nd Resistance Point 4.85
1st Resistance Point 4.80
Last Price 4.74
1st Support Level 4.63
2nd Support Level 4.51
3rd Support Level 4.46

See More

52-Week High 11.78
Fibonacci 61.8% 8.70
Fibonacci 50% 7.75
Fibonacci 38.2% 6.80
Last Price 4.74
52-Week Low 3.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar